Mereo Biopharma (MPH)

Company name:Mereo Biopharma Group Plc
EPIC:MPHTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BZ4G2K23
Market Segment:ASQ1Share Type:DE
WWW Address: GBP0.003
 Price Price Change [%] Bid Offer Open High Low Volume
 37.00 0.0 [0.00] 34.00 40.00 37.00 37.00 37.00 -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 36.25 97.96 0.30 -45.00 - - - 220.00 - 35.00

Mereo Biopharma Key Figures

(at previous day's close)
Market Cap.36.25m
Shares In Issue97.96m
Prev. Close37.00
PE Ratio- 
Dividend Yield-%
EPS - basic-45.00p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-23.62p
Return On Equity (ROE)-97.74%
Operating Margin-%
PEG Factor- 
EPS Growth Rate19.64%
Dividends PS Growth Rate-%
Net Debt9.46m
Gross Gearing51.29%
Quick Assets32.00m
Net Working Capital15.82m
Intangibles / Fixed Assets92.49%
Turnover PS-p
Pre-Tax Profit PS-38.08p
Retained Profit PS-32.70p
Cash PS25.56p
Net Cash PS9.05p
Net Tangible Asset Value PS *0.14p
Net Asset Value PS33.45p
Spread6.00 (15.00%) 

Mereo Biopharma Balance Sheet


Share Price Performance

Sample Period HighLow
1 week37.0035.00
4 weeks37.0035.00
12 weeks68.0035.00
1 year220.0035.00

Share Price Chart (5 years)

Mereo Biopharma Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week37.00--35.000.0137.00
4 weeks36.001.002.7835.000.0337.00
12 weeks60.00-23.00-38.3335.000.0549.79
26 weeks69.50-32.50-46.7635.000.0652.69
1 year196.00-159.00-81.1235.000.1096.77
3 years272.50-235.50-86.4235.000.06152.61
5 years237.50-200.50-84.4235.000.05155.97

Mereo Biopharma Key Management Ratios

Mereo Biopharma Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 0.44 
Tobin's Q Ratio (excl. intangibles)0.74 
Dividend Yield-%
Market-to-Book Ratio1.11 
Price-to-Pre-Tax Profit PS-0.97 
Price-to-Retained Profit PS-1.13 
Price-to-Cash Flow PS-1.57 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS261.60 
Price-to-Cash PS1.45 
Net Working Capital PS16.15 
Price Pct to Working Capital PS2.29%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Mereo Biopharma Financial Ratios

(Leverage Ratios)
Debt Ratio35.87%
Debt-to-Equity Ratio0.56 
Debt-to-Equity Ratio (excl. Intgbl)132.28 
Debt-to-Equity Market Value0.51 
Net Gearing14.07%
Net Gearing (excl. Intangibles)27.32%
Gross Gearing51.29%
Gross Gearing (excl. Intangibles)99.60%
Gearing Under 1 Year24.05%
Gearing Under 1 Year (excl. Intgbl)46.70%
(Liquidity Ratios)
Net Working Capital to Total Assets23.51%
Current Ratio1.98 
Quick Ratio (Acid Test)1.98 
Liquidity Ratio1.55 
Cash & Equiv/Current Assets78.27%
(Solvency Ratios)
Enterprise Value29.53m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.95 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.92 
Total Debt34.51m
Total Debt/Net Current Assets2.18%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-10.61%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs- 
Beta (60-Mnth)Beta (36-Mnth)

Mereo Biopharma Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-73.01%
Return On Assets (ROA)-39.15%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-97.74%
Return On Investment (ROI)-46.48%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debt Collection Period-Days

Mereo Biopharma Dividends

Sorry No Data Available

Mereo Biopharma Fundamentals

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
pre tax profit-33.72--46.95--37.31-m
attributable profit-28.39--38.80--32.03-m
retained profit-28.39--38.80--32.03-m
eps - basic (p)-63.00 -56.00 -45.00 
eps - diluted (p)-63.00 -56.00 -45.00 
dividends per share- - - 

Mereo Biopharma Balance Sheet

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
fixed assets fixed assets0.170.20%0.150.16%0.150.22%m
intangibles intangibles25.8129.75%33.0134.26%32.6348.50%m
fixed investments fixed investments--%2.502.60%2.503.72%m
current assets - other current assets - other--%--%--%m
stocks stocks--%--%--%m
debtors debtors7.208.30%10.6311.04%6.9510.34%m
cash & securities cash & securities53.5861.75%50.0451.95%25.0437.22%m
creditors - short creditors - short3.213.70%9.629.98%16.1824.05%m
creditors - long creditors - long4.304.95%24.2325.16%18.3327.24%m
creditors - other creditors - other--%--%--%m
subordinated loans subordinated loans--%--%--%m
insurance funds insurance funds--%--%--%m
ord cap, reserves ord cap, reserves79.2691.35%62.4864.86%32.7748.71%m
prefs, minorities prefs, minorities--%--%--%m
NAV Basic- - - 
NAV Diluted- - - 

Mereo Biopharma Cash Flow Statement

31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
Operating CF-27.40-32.15-23.14m
Pre-Financing CF-27.03-35.89-22.89m
Retained CF41.33-2.15-24.96m

Mereo Biopharma Brokers

Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Merrill Lynch InternationalMarket Maker(MMF)Broker/DealerMLSBSNCSGB2LBIC
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
Mereo Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191210 10:59:14